Study to Evaluate the Safety and Efficacy of Levetiracetam in Comparison To Magnesium Sulphate in the Management of Severe Pre â?? Eclampsia
- Conditions
- Health Condition 1: O141- Severe pre-eclampsia
- Registration Number
- CTRI/2020/02/023194
- Lead Sponsor
- BLDE Deemed to be University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
1.All pregnant women with gestational age above 28 weeks presenting with features of severe pre eclampsia and imminent eclampsia during the period will be recruited into the study
2.Patients giving informed and written consent for investigations
1.Patients who were diagnosed with other causes of convulsions in pregnancy like cerebral malaria and epilepsy
2.Chronic hypertensive pregnant females
3.Pregnant females with fetal anomalies detected on USG
4.Patients who withdraw the consent for further participation in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the efficacy of Levetiracetam as an alternative to Magnesium sulphate in the prevention of convulsions in severe preeclampsia and imminent eclampsia. <br/ ><br>To evaluate the neonatal outcomes in babies exposed to levetiracetam and magnesium sulphate <br/ ><br>Timepoint: 1.Adverse effects st the time of administration <br/ ><br>2. Occurence of seizures inspite of giving the drug <br/ ><br>3. adverse effects of the drug at 24 hours <br/ ><br>4 Adverse effects of drugs between 24 hours to 7 days after the administration <br/ ><br>5. advesre effect of the drug at birth on the neonate <br/ ><br>6. Adverse effect of the drug between 24 hours to 7 days after administration of the drug on the neonate
- Secondary Outcome Measures
Name Time Method To study the perinatal outcoe after the exposure to the drugsTimepoint: adverse effect of the drug on the neonate at 1 month after the delivery